Arcutis Biotherapeutics, Inc. (ARQT) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
13.87
↑+73% vs avg
5yr avg: 8.01
30Y Low2.5·High19.5
ROE
↑
-9.3%
↓+91% vs avg
5yr avg: -98.9%
30Y Low-176%·High-9%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ARQT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Arcutis Biotherapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.6B | $3.7B | $1.7B | $224M | $814M | $1.0B | $1.0B | — | — | — |
| Enterprise Value | $2.5B | $3.7B | $1.7B | $341M | $963M | $1.0B | $943M | — | — | — |
| P/E Ratio → | -158.92 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.87 | 9.82 | 8.57 | 3.76 | 220.96 | — | — | — | — | — |
| P/B Ratio | 13.87 | 19.50 | 10.70 | 2.52 | 3.89 | 3.44 | 3.71 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ARQT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 9.73 | 8.77 | 5.73 | 261.36 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
ARQT Profitability
Margins and return-on-capital ratios measuring operating efficiency
Arcutis Biotherapeutics, Inc. earns an operating margin of -3.3%. Operating margins have expanded from -404.5% to -3.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -9.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.2% | 90.2% | 90.3% | 91.6% | 79.5% | — | — | — | — | — |
| Operating Margin | -3.3% | -3.3% | -65.3% | -404.5% | -8183.0% | — | — | — | — | — |
| Net Profit Margin | -4.3% | -4.3% | -71.3% | -439.8% | -8449.8% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -9.3% | -9.3% | -113.8% | -175.8% | -122.8% | -72.6% | -72.9% | -108.4% | — | — |
| ROA | -4.1% | -4.1% | -40.6% | -66.3% | -72.6% | -58.4% | -67.0% | -53.1% | -70.1% | -130.3% |
| ROIC | -5.2% | -5.2% | -47.8% | -64.0% | -71.2% | -63.5% | -82.3% | — | — | — |
| ROCE | -4.3% | -4.3% | -45.6% | -68.3% | -76.7% | -63.5% | -72.4% | -57.4% | -76.6% | -131.3% |
ARQT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $43M exceeds total debt of $6M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.70 | 2.32 | 0.97 | 0.26 | 0.02 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.19 | 0.25 | 1.33 | 0.71 | -0.07 | -0.22 | -0.62 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -0.24 | -0.24 | -4.13 | -7.72 | -18.90 | — | — | — | — | — |
Net cash position: cash ($43M) exceeds total debt ($6M)
ARQT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Arcutis Biotherapeutics, Inc.'s current ratio of 3.17x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 7.08x to 3.17x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.17 | 3.17 | 4.15 | 7.08 | 11.57 | 12.09 | 12.96 | 20.33 | 19.12 | 5.52 |
| Quick Ratio | 2.99 | 2.99 | 3.97 | 6.80 | 11.37 | 12.09 | 12.96 | 20.33 | 19.12 | 5.52 |
| Cash Ratio | 1.70 | 1.70 | 2.81 | 5.83 | 10.83 | 11.66 | 12.58 | 19.34 | 19.06 | 4.94 |
| Asset Turnover | — | 0.87 | 0.56 | 0.17 | 0.01 | — | — | — | — | — |
| Inventory Turnover | 1.62 | 1.62 | 1.32 | 0.38 | 0.10 | — | — | — | — | — |
| Days Sales Outstanding | — | 141.92 | 135.69 | 158.03 | 837.54 | — | — | — | — | — |
ARQT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Arcutis Biotherapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $127M | $121M | $69M | $55M | $49M | $36M | $38M | $36M | $1M |
Peer Comparison
Compare ARQT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ARQTYou | $3B | -158.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 DERM | $102M | -6.9 | — | — | 62.8% | -24.4% | -72.6% | -56.8% | — |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 PRGO | $2B | -1.1 | 7.4 | 11.1 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 DAWN | $2B | -20.7 | — | — | 89.1% | -80.8% | -22.7% | -30.5% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 HRMY | $2B | 11.6 | 5.6 | 5.2 | 77.2% | 24.0% | 20.8% | 42.0% | 1.0 |
 VNDA | $378M | -1.7 | — | — | 94.0% | -70.0% | -50.9% | -32.2% | — |
 SKIN | $118M | -5.7 | 7331.2 | 3.2 | 65.3% | -6.9% | -16.8% | -6.8% | 10519.4 |
 ABT | $151B | 11.4 | 15.8 | 23.8 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See ARQT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARQT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARQT vs DERM
Side-by-side business, growth, and profitability comparison vs Journey Medical Corporation.
Start ComparisonARQT — Frequently Asked Questions
Quick answers to the most common questions about buying ARQT stock.
What is Arcutis Biotherapeutics, Inc.'s P/E ratio?
Arcutis Biotherapeutics, Inc.'s current P/E ratio is -158.9x. This places it at the 50th percentile of its historical range.
What is Arcutis Biotherapeutics, Inc.'s ROE?
Arcutis Biotherapeutics, Inc.'s return on equity (ROE) is -9.3%. The historical average is -96.5%.
Is ARQT stock overvalued?
Based on historical data, Arcutis Biotherapeutics, Inc. is trading at a P/E of -158.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Arcutis Biotherapeutics, Inc.'s profit margins?
Arcutis Biotherapeutics, Inc. has 90.2% gross margin and -3.3% operating margin.